Progress in developing virus-like particle influenza vaccines

References

• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179–186.
   PubMed Web of Science ®Google Scholar
• Dushoff J, Plotkin JB, Viboud C, et al. Mortality due to influenza in the United States–an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006 Jan 15;163(2):181–187.
   PubMed Web of Science ®Google Scholar
• Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9(10):e1003657.
   PubMed Web of Science ®Google Scholar
• Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009 Jun 18;459(7249):931–9002E.
   PubMed Web of Science ®Google Scholar
• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013 May 16;368(20):1888–1897.
   PubMed Web of Science ®Google Scholar
• Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013 Dec 26;369(26):2564–2566.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007 May 10;25(19):3871–3878.
   PubMed Web of Science ®Google Scholar
• Hossain MJ, Bourgeois M, Quan FS, et al. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clinical Vaccine Immunol: CVI. 2011 Dec;18(12):2010–2017.
   PubMed Web of Science ®Google Scholar
• Quan FS, Huang C, Compans RW, et al. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007 Apr;81(7):3514–3524.
   PubMed Web of Science ®Google Scholar
• Quan FS, Steinhauer D, Huang C, et al. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008 Jun 19;26(26):3352–3361.
   PubMed Web of Science ®Google Scholar
• Wang BZ, Quan FS, Kang SM, et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol. 2008 Dec;82(23):11813–11823.
   PubMed Web of Science ®Google Scholar
• Ross TM, Mahmood K, Crevar CJ, et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One. 2009;4(6):e6032.
   PubMed Web of Science ®Google Scholar
• Quan FS, Yoo DG, Song JM, et al. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol. 2009 May;83(9):4489–4497.
   PubMed Web of Science ®Google Scholar
• Quan FS, Vunnava A, Compans RW, et al. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010;5(2):e9161.
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Vunnava A, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol. 2010 Aug;84(15):7760–7769.
   PubMed Web of Science ®Google Scholar
• Wang BZ, Xu R, Quan FS, et al. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One. 2010;5(11):e13972.
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim MC, Lee BJ, et al. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology. 2012 Sep 1;430(2):127–135.
   PubMed Web of Science ®Google Scholar
• Giles BM, Bissel SJ, Craigo JK, Dealmeida DR, Wiley CA, Tumpey TM, et al. Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice. J Virol. 2012 Feb;86(3):1500–1513.
   PubMed Web of Science ®Google Scholar
• Lee DH, Bae SW, Park JK, et al. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine. 2013 Jul 11;31(32):3268–3273.
   PubMed Web of Science ®Google Scholar
• Rezaei F, Mirshafiey A, Shahmahmoodi S, et al. Influenza virus-like particle containing two different subtypes of hemagglutinin confers protection in mice against lethal challenge with A/PR8 (H1N1) and A/HK (H3N2) viruses. Iran Red Crescent Med J. 2013 Jan;15(1):75–82.
   PubMed Web of Science ®Google Scholar
• Quan FS, Ko EJ, Kwon YM, et al. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol. 2013 Dec;26(6):385–395.
   PubMed Web of Science ®Google Scholar
• Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005;18(1):244–251.
   PubMed Web of Science ®Google Scholar
• Pushko P, Kort T, Nathan M, et al. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010 Jul 5;28(30):4771–4776.
   PubMed Web of Science ®Google Scholar
• Pyo HM, Masic A, Woldeab N, et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine. 2012 Feb 8;30(7):1297–1304.
   PubMed Web of Science ®Google Scholar
• Inn KS, Lee GJ, Quan FS. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Immunol Invest. 2014;43(3):236–254.
   PubMed Web of Science ®Google Scholar
• Schwartzman LM, Cathcart AL, Pujanauski LM, et al. An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of Influenza A virus. MBio. 2015;6(4):e01044.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Bu F, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005 Dec 30;23(50):5751–5759.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Van Hoeven N, et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine. 2007 May 22;25(21):4283–4290.
   PubMed Web of Science ®Google Scholar
• Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 2007 Sep;20(3):441–452.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to Influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3(1):e1501.
   PubMed Web of Science ®Google Scholar
• Mahmood K, Bright RA, Mytle N, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 2008 Oct 3;26(42):5393–5399.
   PubMed Web of Science ®Google Scholar
• Crevar CJ, Ross TM. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J. 2008;5:131.
   PubMed Web of Science ®Google Scholar
• Kang SM, Yoo DG, Lipatov AS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 2009;4(3):e4667.
   PubMed Web of Science ®Google Scholar
• Tao P, Luo M, Zhu D, et al. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol. 2009 Jul;22(4):273–281.
   PubMed Web of Science ®Google Scholar
• Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine. 2009 Jan 22;27(4):530–541.
   PubMed Web of Science ®Google Scholar
• Perrone LA, Ahmad A, Veguilla V, et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol. 2009 Jun;83(11):5726–5734.
   PubMed Web of Science ®Google Scholar
• Wu CY, Yeh YC, Yang YC, et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One. 2010;5(3):e9784.
   PubMed Web of Science ®Google Scholar
• Song JM, Hossain J, Yoo DG, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology. 2010 Sep 15;405(1):165–175.
   PubMed Web of Science ®Google Scholar
• Song JM, Van Rooijen N, Bozja J, et al. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):757–761.
   PubMed Web of Science ®Google Scholar
• Lee DH, Park JK, Lee YN, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine. 2011 May 23;29(23):4003–4007.
   PubMed Web of Science ®Google Scholar
• Park JK, Lee DH, Youn HN, et al. Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respi Viruses. 2013 May;7(3):340–348.
   PubMed Web of Science ®Google Scholar
• Schmeisser F, Adamo JE, Blumberg B, et al. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine. 2012 May 14;30(23):3413–3422.
   PubMed Web of Science ®Google Scholar
• Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clinical Vaccine Immunol: CVI. 2012 Feb;19(2):128–139.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Pearce MB, Florese R, et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology. 2013 Jul 20;442(1):67–73.
   PubMed Web of Science ®Google Scholar
• Choi JG, Kim MC, Kang HM, et al. Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens. Vet Microbiol. 2013 Mar 23;162(2–4):623–630.
   PubMed Web of Science ®Google Scholar
• Li X, Pushko P, Tretyakova I. Recombinant hemagglutinin and virus-like particle vaccines for H7N9 influenza virus. J Vaccines Vaccin. 2015 Jun;6(3). doi:10.4172/2157-7560.1000287.
   PubMedGoogle Scholar
• Chung KY, Coyle EM, Jani D, et al. ISCOMATRIX adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine. 2015 Jul 31;33(32):3953–3962.
   PubMed Web of Science ®Google Scholar
• Liu YV, Massare MJ, Pearce MB, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine. 2015 Apr 27;33(18):2152–2158.
   PubMed Web of Science ®Google Scholar
• Ren Z, Ji X, Meng L, et al. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus. Virus Res. 2015 Mar 16;200:9–18.
   PubMed Web of Science ®Google Scholar
• Xue C, Tian G, Chen X, et al. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens. Virus Res. 2015 Jan;2(195):35–42.
   Web of Science ®Google Scholar
• Rodriguez-Limas WA, Sekar K, Tyo KE. Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development. Curr Opin Biotechnol. 2013 Dec;24(6):1089–1093.
   PubMed Web of Science ®Google Scholar
• Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol. 2013 Jan;53(1):92–107.
   PubMed Web of Science ®Google Scholar
• Song JM, Wang BZ, Park KM, et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One. 2011;6(1):e14538.
   PubMed Web of Science ®Google Scholar
• Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol. 2001 Jul;75(13):6154–6165.
   PubMed Web of Science ®Google Scholar
• Komarova TV, Baschieri S, Donini M, et al. Transient expression systems for plant-derived biopharmaceuticals. Expert Rev Vaccines. 2010 Aug;9(8):859–876.
   PubMed Web of Science ®Google Scholar
• Kong WP, Hood C, Yang ZY, et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. PNAS. 2006 Oct 24;103(43):15987–15991.
   PubMed Web of Science ®Google Scholar
• Kim MC, Lee JW, Choi HJ, et al. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. Journal Controlled Release: Off J Controlled Release Soc. 2015 Jul 28;210:208–216.
   PubMed Web of Science ®Google Scholar
• Dubois B, Massacrier C, Caux C. Selective attraction of naive and memory B cells by dendritic cells. J Leukoc Biol. 2001 Oct;70(4):633–641.
   PubMed Web of Science ®Google Scholar
• Qi H, Egen JG, Huang AY, et al. Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science. 2006 Jun 16;312(5780):1672–1676.
   PubMed Web of Science ®Google Scholar
• Wykes M, Pombo A, Jenkins C, et al. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol. 1998 Aug 1;161(3):1313–1319.
   PubMed Web of Science ®Google Scholar
• Del Pilar Martin M, Weldon WC, Zarnitsyn VG, et al. Local response to microneedle-based influenza immunization in the skin. MBio. 2012;3(2):e00012–12.
   PubMed Web of Science ®Google Scholar
• Pearton M, Kang SM, Song JM, et al. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine. 2010 Aug 23;28(37):6104–6113.
   PubMed Web of Science ®Google Scholar
• Jacobs BB, Huseby RA. Growth of tumors in allogeneic hosts following organ culture explantation. Transplantation. 1967 May;5(3):410–419.
   PubMedGoogle Scholar
• Billingham RE. The passenger cell concept in transplantation immunology. Cell Immunol. 1971 Feb;2(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004 Nov 25;351(22):2295–2301.
   PubMed Web of Science ®Google Scholar
• Pape KA, Catron DM, Itano AA, et al. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity. 2007 Apr;26(4):491–502.
   PubMed Web of Science ®Google Scholar
• Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 2000 Apr;21(4):163–165.
   PubMedGoogle Scholar
• Huber VC, McKeon RM, Brackin MN, et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006 Sep;13(9):981–990.
   PubMed Web of Science ®Google Scholar
• Patel JM, Kim MC, Vartabedian VF, et al. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomed: Nanotechnol Biol Med. 2015 Jul;11(5):1097–1107.
   PubMed Web of Science ®Google Scholar
• Krammer F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J. 2015 May;10(5):690–701.
   PubMed Web of Science ®Google Scholar
• Claas EC, Osterhaus AD, Van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998 Feb 14;351(9101):472–477.
   PubMed Web of Science ®Google Scholar
• Szecsi J, Boson B, Johnsson P, et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J. 2006;3:70.
   PubMed Web of Science ®Google Scholar
• Smith GE, Flyer DC, Raghunandan R, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013 Sep 13;31(40):4305–4313.
   PubMed Web of Science ®Google Scholar
• Klausberger M, Wilde M, Palmberger D, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine. 2014 Jan 9;32(3):355–362.
   PubMed Web of Science ®Google Scholar
• Burges H, Croizier G, Huber J. A review of safety tests on baculoviruses. Entomopaga. 1980;25(4):329–340.
   Web of Science ®Google Scholar
• Kenoutis C, Efrose RC, Swevers L, et al. Baculovirus-mediated gene delivery into mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression. J Virol. 2006 Apr;80(8):4135–4146.
   PubMed Web of Science ®Google Scholar
• López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011 Oct 13;29(44):7826–7834.
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol. 2011 Nov;85(21):10945–10954.
   PubMed Web of Science ®Google Scholar
• D’Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010 Jun;8(5):607–619.
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trepanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010;5(12):e15559.
   PubMed Web of Science ®Google Scholar
• Chen Q, Lai H. Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother. 2013 Jan;9(1):26–49.
   PubMed Web of Science ®Google Scholar
• Low JG, Lee LS, Ooi EE, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 2014 Sep 3;32(39):5041–5048.
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983 Jul 7;309(1):13–17.
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012 Feb;18(2):274–280.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013 Oct;19(10):1305–1312.
   PubMed Web of Science ®Google Scholar
• Kim MC, Song JM, E O, et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Therapy: Journal Am Soc Gene Ther. 2013 Feb;21(2):485–492.
   PubMed Web of Science ®Google Scholar
• Wohlbold TJ, Nachbagauer R, Xu H, et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio. 2015;6(2):e02556.
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Wang T, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 2010;1:1.
   Web of Science ®Google Scholar